Pharming Group N.V. (PHAR) Liabilities and Shareholders Equity (2019 - 2024)
Pharming (PHAR) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $400.0 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Liabilities and Shareholders Equity fell 13.58% year-over-year to $400.0 million, compared with a TTM value of $1.7 billion through Dec 2024, changed 0.37%, and an annual FY2024 reading of $400.0 million, down 13.58% over the prior year.
- Liabilities and Shareholders Equity was $400.0 million for Q4 2024 at Pharming, down from $462.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $462.9 million in Q4 2023 and bottomed at $397.3 million in Q4 2021.
- Average Liabilities and Shareholders Equity over 5 years is $418.4 million, with a median of $406.3 million recorded in 2020.
- The sharpest move saw Liabilities and Shareholders Equity surged 60.84% in 2020, then fell 13.58% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $406.3 million in 2020, then fell by 2.21% to $397.3 million in 2021, then increased by 7.17% to $425.8 million in 2022, then rose by 8.7% to $462.9 million in 2023, then dropped by 13.58% to $400.0 million in 2024.
- Business Quant data shows Liabilities and Shareholders Equity for PHAR at $400.0 million in Q4 2024, $462.9 million in Q4 2023, and $425.8 million in Q4 2022.